{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:10:35Z","timestamp":1784196635569,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH\u20101133701D"],"award-info":[{"award-number":["TCVGH\u20101133701D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH\u20101140701D"],"award-info":[{"award-number":["TCVGH\u20101140701D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH\u2010YM1140115"],"award-info":[{"award-number":["TCVGH\u2010YM1140115"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Therapy for chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted agents such as Bruton's tyrosine kinase (BTK) inhibitors and BCL\u20102 inhibitors. Approved first\u2010line options include acalabrutinib, a second\u2010generation BTK inhibitor, and the fixed\u2010duration combination venetoclax\u2013obinutuzumab, yet real\u2010world head\u2010to\u2010head data are scarce.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using the TriNetX global federated health database, we retrospectively compared outcomes in treatment\u2010na\u00efve patients with TP53\u2010unmutated CLL who received either regimen as initial therapy. After applying eligibility criteria and 1:1 propensity score matching, 669 matched pairs were analyzed. The primary endpoint was time to next treatment (TTNT); secondary endpoints included overall survival (OS) and adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The results showed that patients treated with venetoclax plus obinutuzumab had a significantly longer\n TTNT<\/jats:styled-content>\n (median not reached vs. 47.7\u2009months) and improved 4\u2010year\n OS<\/jats:styled-content>\n . Across all subgroups, the venetoclax\u2010based regimen performed better. Cytopenias and infections were more common with venetoclax\u2013obinutuzumab\u2014neutropenia 54.3% versus 33.3%, thrombocytopenia 45.9% versus 31.9%, febrile neutropenia 7.1% versus 3.4%, and tumor lysis syndrome 6.3% versus 2.3%. Acalabrutinib caused fewer severe hematologic toxicities.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In real\u2010world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first\u2010line therapy in patients with TP53 wild\u2010type CLL.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.72022","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:15:38Z","timestamp":1780636538000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment\u2010Naive Chronic Lymphocytic Leukemia: A Real\u2010World Propensity Score\u2010Matched Study"],"prefix":"10.1002","volume":"15","author":[{"given":"Po\u2010Wei","family":"Liao","sequence":"first","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan"},{"name":"Department of Life Science Tunghai University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor\u2010Sheng","family":"Ko","sequence":"additional","affiliation":[{"name":"School of Medicine, National Taiwan University College of Medicine Taipei Taiwan"},{"name":"Department of Hematological Oncology National Taiwan University Cancer Center Taipei City Taiwan"},{"name":"Division of Hematology, Department of Internal Medicine National Taiwan University Hospital Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Chen","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan"},{"name":"Department of Nursing Taichung Veterans General Hospital Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Ting","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Life Science Tunghai University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh\u2010Lin Jerry","family":"Teng","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan"},{"name":"Department of Life Science Tunghai University Taichung Taiwan"},{"name":"Department of Post\u2010Baccalaureate Medicine, College of Medicine National Chung Hsing University Taichung Taiwan"},{"name":"School of Medicine, Chung Shan Medical University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.06.003"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0018"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000120"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"e_1_2_13_19_1","first-page":"81","article-title":"Use of BTK Inhibitors in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): A Practical Guidance","volume":"12","author":"St\u2010Pierre F.","year":"2022","journal-title":"Blood and Lymphatic Cancer"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19613"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2255326"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174750"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02260-7"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00196-7"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211989"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167875"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00220"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114248"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.110"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626846"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127674"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0063"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04353-9"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212019"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.010"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2257"},{"issue":"7","key":"e_1_2_13_41_1","article-title":"COVID\u201019 in Patients Receiving CD20\u2010Depleting Immunochemotherapy for B\u2010Cell Lymphoma","volume":"5","author":"Gaitzsch E.","year":"2021","journal-title":"Hema"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.012"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180955"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013792"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72022","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:02:19Z","timestamp":1784196139000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cam4.72022"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72022","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72022"}}